CooperCompanies keeping CooperSurgical; shares drop on updated guidance

CooperCompanies, a San Ramon-based company traded on the NASDAQ under the ticker COO, has announced a strategic decision to retain its CooperSurgical unit following a comprehensive review process. The company's Board of Directors unanimously agreed that retaining CooperSurgical would be more beneficial for shareholders, rather than pursuing a potential sale. The strategic review commenced in December 2025, with the aim of identifying opportunities to maximize long-term shareholder value.

Despite receiving offers from various parties, the Board deemed the proposed valuations as not aligning with the best interests of shareholders. This assessment was influenced by temporary factors, such as recent developments in the non-hormonal intrauterine device (IUD) market and the impact of a recent fertility litigation settlement.

In light of this decision, CooperCompanies has expanded its share repurchase authorization, increasing it from $2 billion to $3 billion. As of the current fiscal year, the company has repurchased shares worth $445 million. To further enhance its operations, the company has added two independent directors with expertise in healthcare and medical device CEO roles.

President and CEO Al White emphasized that the strategic review process revealed opportunities to strengthen execution and accelerate innovation. In response, CooperCompanies is implementing operational changes, including expanding CooperVision's global sales and marketing organization, introducing cost reduction and efficiency programs, and refining inventory and logistics approaches. The company is also set to open The Vision Centre, CooperVision's global R&D innovation hub, on September 23, 2026.

CooperCompanies' strategic focus remains centered on supporting CooperVision, with investments prioritized towards commercial strengths and organic growth. CooperSurgical, on the other hand, will concentrate on organic growth initiatives and operational performance improvements. The company is organized into two business units: CooperVision, which specializes in contact lenses, and CooperSurgical, catering to fertility and women's healthcare markets.

With a workforce of over 15,000 employees and a global presence in more than 130 countries, CooperCompanies continues to solidify its position in the market, leveraging AI support in the creation of this report. For further details, readers are encouraged to review the full article.